Orphan Disease Natural History Grants Latest FDA Incentive For Drug Development
Executive Summary
Agency will make $2m available in 2017.
You may also be interested in...
Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies
NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says
CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.
Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.